$282.92
0.46% day before yesterday
Nasdaq, Jan 02, 10:00 pm CET
ISIN
US45784P1012
Symbol
PODD

Insulet Corporation Stock price

$282.92
-26.08 8.44% 1M
-18.70 6.20% 6M
-1.32 0.46% YTD
+26.07 10.15% 1Y
-11.47 3.90% 3Y
+31.30 12.44% 5Y
+245.86 663.41% 10Y
+266.96 1,672.68% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
-1.32 0.46%

New AI Insights on Insulet Corporation Insights AI Insights on Insulet Corporation

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$19.9b
Enterprise Value
$20.3b
Net debt
$387.6m
Cash
$627.2m
Shares outstanding
70.4m
Valuation (TTM | estimate)
P/E
81.3 | 56.8
P/S
7.9 | 7.2
EV/Sales
8.1 | 7.4
EV/FCF
49.8
P/B
14.4
Financial Health
Equity Ratio
39.2%
Return on Equity
34.5%
ROCE
18.3%
ROIC
-
Debt/Equity
0.7
Financials (TTM | estimate)
Revenue
$2.5b | $2.7b
EBITDA
$524.4m | $624.7m
EBIT
$436.9m | $478.0m
Net Income
$246.2m | $350.2m
Free Cash Flow
$407.7m
Growth (TTM | estimate)
Revenue
27.1% | 32.6%
EBITDA
36.5% | 60.3%
EBIT
42.8% | 54.7%
Net Income
-41.5% | -16.3%
Free Cash Flow
86.9%
Margin (TTM | estimate)
Gross
71.5%
EBITDA
20.8% | 22.8%
EBIT
17.3%
Net
9.8% | 12.8%
Free Cash Flow
16.2%
More
EPS
$3.5
FCF per Share
$5.8
Short interest
4.5%
Employees
4k
Rev per Employee
$530.0k
Show more

Is Insulet Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Insulet Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

33 Analysts have issued a Insulet Corporation forecast:

30x Buy
91%
3x Hold
9%

Analyst Opinions

33 Analysts have issued a Insulet Corporation forecast:

Buy
91%
Hold
9%

Financial data from Insulet Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
2,522 2,522
27% 27%
100%
- Direct Costs 720 720
18% 18%
29%
1,802 1,802
31% 31%
71%
- Selling and Administrative Expenses 1,095 1,095
26% 26%
43%
- Research and Development Expense 271 271
35% 35%
11%
524 524
37% 37%
21%
- Depreciation and Amortization 88 88
12% 12%
3%
EBIT (Operating Income) EBIT 437 437
43% 43%
17%
Net Profit 246 246
42% 42%
10%

In millions USD.

Don't miss a Thing! We will send you all news about Insulet Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Insulet Corporation Stock News

Neutral
Business Wire
18 days ago
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 11:15 a.m. (Pacific Time). The live webcast and replay of the presentation will be accessibl...
Neutral
Business Wire
19 days ago
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod brand of products, has announced the expansion of its U.S. Pod recycling program, which is now available to all U.S. customers. “Here at Insulet, our mission is to transform the lives of people with diabetes, and we are equally co...
Positive
Market Watch
23 days ago
The healthcare sector of the U.S. stock market as a whole is cheaply priced, which can make it attractive to investors concerned that the S&P 500 has gotten too expensive several years into a bull market.
More Insulet Corporation News

Company Profile

Insulet Corp. is a medical device company. The firm engages in the development, manufacture and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.

Head office United States
CEO Ashley McEvoy
Employees 3,900
Founded 2000
Website www.omnipod.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today